Kusajili – Clinical trials directory

Result of your search per sponsor: Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)

Man Max 99 years
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005) Update Il y a 4 ans

A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia To assess the effect of Tamsulosin OCAS 0.4 mg o.d. compared to placebo on improvement of nocturnal voiding frequency, in subjects with LUTS associated with BPH over 12 weeks.

Country None
organs None
Specialty None

Closed trial

More information